JH-VIII-49

CAS No. 2209084-73-9

JH-VIII-49 ( —— )

Catalog No. M13522 CAS No. 2209084-73-9

JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JH-VIII-49
  • Note
    Research use only, not for human use.
  • Brief Description
    JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
  • Description
    JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM); displays excellent selectivity against a panel of 468 kinases at a concentration of 10 uM, only 4 has >90% inhibition; induces a dose-dependent inhibition of S727-STAT1 phosphorylation in HepG2 cells (at 5 uM).
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2209084-73-9
  • Formula Weight
    428.66
  • Molecular Formula
    C30H40N2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (3S,8S,10R,13S,14S,17S)-17-(isoquinolin-7-yl)-N,N,10,13-tetramethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-amine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. John M. Hatcher, et al. ACS Med. Chem. Lett. DOI: 10.1021/acsmedchemlett.8b00011
molnova catalog
related products
  • NVP-2

    NVP-2 is apotent, selective, ATP-competitive CDK9 inhibitor with IC50 of <0.514 nM (CDK9/CyclinT).

  • Amt-87

    Amt-87 is a HIV latency-reversal agent that reactivates latent HIV at the transcriptional level, promotes phosphorylation of CDK9 T-loop at Thr186.

  • Roscovitine

    A potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively.